查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886899

mRNA疫苗市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，以及2024年至2032年的預測

mRNA Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

mRNA疫苗市場成長驅動因子

隨著藥物創新和傳染病防治策略的變革，全球mRNA疫苗市場持續快速發展。 2024年，該市場規模預計將達到89.1億美元，主要得益於基因技術的進步、強大的研發管線以及新冠疫情後持續的需求。到2025年，隨著新冠疫苗需求的正常化，預計市場規模將調整至60.1億美元，但長期前景仍樂觀。到2032年，mRNA疫苗市場預計將顯著成長，達到204.3億美元，主要得益於其在傳染病、腫瘤、自體免疫疾病和個人化醫療等領域應用的持續拓展。

截至2024年，北美將以35.13%的市佔率引領全球市場。這得歸功於北美強大的醫療基礎設施、較高的疫苗接種率、眾多大型生物製藥企業的存在以及政府的大量投資。 Moderna、輝瑞-BioNTech和CureVac等領導企業正透過持續的研發投入和拓展下一代疫苗產品組合來增強其競爭優勢。

市場動態

市場推動因素

推動市場成長的關鍵因素是加大研發投入，致力於將mRNA疫苗的應用範圍擴展到新冠肺炎以外的其他疾病。以mRNA為基礎的新冠肺炎疫苗的成功加速了全球對開發類似疫苗的興趣，這些疫苗可以預防流感、呼吸道合胞病毒（RSV）、愛滋病以及各種新興傳染病。 Moderna和BioNTech等公司正在加大投資；例如，Moderna 已宣布計劃在 2024 年至 2028 年間投資 250 億美元用於研發。此類投資可確保強大的產品線和持續創新。

此外，各組織正利用人工智慧加速臨床開發。輝瑞的 AI 驅動智慧數據查詢 (SDQ) 系統在疫​​情期間加速了臨床數據審查，凸顯了 AI 驅動型疫苗開發的潛力。

市場限制因子

監理挑戰持續限制市場成長。儘管疫情期間審批速度加快，但其他疾病的 mRNA 疫苗仍面臨漫長的驗證流程，尤其是在美國 FDA 的研究性新藥 (IND) 和生物製品許可申請 (BLA) 流程中。標準化生產方案、確保冷鏈需求以及維持 mRNA 穩定性等複雜因素進一步增加了監管壓力。

市場機會

mRNA 疫苗應用範圍的擴大帶來了巨大的機會。除了傳染病領域，mRNA技術正被探索用於癌症疫苗、自體免疫疾病和罕見遺傳疾病的研發。在強大的研發管線和不斷增加的全球臨床試驗的推動下，非新冠肺炎領域的mRNA疫苗預計將在未來十年加速發展。世界衛生組織（世衛組織）提出的2024年推動禽流感（H5N1）先進mRNA疫苗研發的倡議，進一步增強了未來的發展機會。

市場挑戰

大眾對疫苗接種的猶豫仍然是一項重大挑戰，尤其是在資訊不實、認知度低和醫療資源匱乏的地區。智慧財產權糾紛，例如Moderna和Arbutus之間的糾紛，也影響市場競爭格局。此外，大規模mRNA疫苗生產的複雜性（需要低溫儲存和先進的脂質奈米顆粒遞送系統）也為新興市場帶來了生產方面的挑戰。

市場趨勢

技術進步

主要趨勢包括自擴增mRNA的開發、改良的脂質奈米顆粒（LNP）遞送系統、人工智慧賦能的臨床研究。這些創新正在提高疫苗效力、減少接種頻率並降低生產成本。美國FDA和歐洲藥品管理局（EMA）等監管機構的持續支持也在加速疫苗的研發週期。

策略聯盟

整個產業的合作關係正在增加。 BioNTech與CEPI和Mpox在2023年合作開發瘧疾疫苗，反映了全球對新興傳染病的策略關注。

依類型劃分的洞見

依類型劃分

2024年，在全美疫苗接種運動的推動下，新冠疫苗細分市場引領市場。同時，非新冠疫苗市場正在快速擴張，呼吸道合胞病毒（RSV）、流感、狂犬病和癌症疫苗等研發管線正逐漸展現出臨床應用價值。

依適應症劃分

2024年，由於需要加強免疫接種以及變異株的出現，新冠病毒感染病例佔最大。包括Moderna公司獲得FDA批准的mRESVIA（2024年）在內的呼吸道合胞病毒疫苗展現出強勁的成長潛力。

依通路劃分

由於疫情期間大規模疫苗接種基礎設施的建設，醫院和零售藥局在2024年成為市場的主要推動力。政府機構也透過大規模疫苗接種計畫做出了重大貢獻。

區域展望

北美市場在2024年將佔主導地位，市場規模達31.3億美元，這得益於其強大的研發能力、健全的監管框架和大規模的生產能力。

歐洲則位居第二，這得益於其有利的疫苗接種政策和較高的疫苗接種率。

由於傳染病日益流行和生物技術投資不斷增長，預計亞太地區將在未來幾年內實現最快增長。

其他地區，市場持續受益於新的生產基地，例如 BioNTech 在盧安達的 mRNA 生產設施（2023 年）。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵洞察

  • 主要公司新產品發布
  • 主要公司產品線分析
  • mRNA 疫苗市場的技術進步
  • 主要疾病的發生率/盛行率（2024）
  • 關鍵產業趨勢（併購、合作及其他）

第五章 全球mRNA疫苗市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依類型劃分
    • 新冠病毒疫苗
    • 非新冠病毒疫苗
  • 市場分析、洞察與預測 - 依適應症劃分
    • 新冠病毒感染
    • 呼吸道合胞病毒（RSV）感染
    • 其他
  • 市場分析、洞察與預測 - 依分銷管道劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第六章 北美mRNA疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲mRNA疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 其他地區歐洲

第八章 亞太地區mRNA疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 其他mRNA疫苗市場分析、洞察與預測（2019-2032）

第十章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • Moderna Inc.
  • BioNTech
  • CureVac SE
  • GSK plc
  • 賽諾菲
  • 輝瑞公司
  • 金諾生物製藥股份有限公司
  • 華生生技有限公司
  • Arcturus Therapeutics
Product Code: FBI113546

Growth Factors of mRNA vaccines Market

The global mRNA vaccines market continues to evolve rapidly as pharmaceutical innovations and infectious disease management strategies transform global vaccine development. The market was valued at USD 8.91 billion in 2024, supported by advances in genetic technologies, strong R&D pipelines, and sustained demand following the COVID-19 pandemic. In 2025, the market size is expected to adjust to USD 6.01 billion, reflecting normalization in COVID-19 vaccine demand; however, long-term prospects remain promising. By 2032, the mRNA vaccines market is projected to grow significantly, reaching USD 20.43 billion, driven by increasing applications across infectious diseases, oncology, autoimmune disorders, and personalized medicine.

North America dominated the global market in 2024 with 35.13% share, backed by strong healthcare infrastructure, high vaccine adoption, major biopharmaceutical manufacturers, and substantial government investment. Key players such as Moderna, Pfizer-BioNTech, and CureVac have strengthened their competitive positioning through continual R&D investments and the expansion of next-generation vaccine portfolios.

Market Dynamics

Market Drivers

A primary growth driver is the increase in research and development activities focused on expanding mRNA vaccine applications beyond COVID-19. The success of mRNA-based COVID-19 vaccines accelerated global interest in developing similar vaccines for influenza, RSV, HIV, and various emerging infectious diseases. Companies such as Moderna and BioNTech are expanding their investment commitments-Moderna, for instance, announced plans to invest USD 25 billion in R&D between 2024 and 2028. Such investments ensure robust pipelines and continued innovation.

Moreover, organizations are leveraging artificial intelligence for faster clinical development. Pfizer's adoption of the AI-driven Smart Data Query (SDQ) system accelerated clinical data review during the pandemic, highlighting the potential of AI-enabled vaccine development.

Market Restraints

Regulatory challenges continue to restrain market growth. Despite accelerated approvals during the pandemic, mRNA vaccines for other diseases face lengthy validation processes, particularly in the U.S. FDA's IND and BLA pathways. Complexities in standardizing manufacturing protocols, ensuring cold-chain requirements, and maintaining mRNA stability add further regulatory pressure.

Market Opportunities

Expanding applications of mRNA vaccines present substantial opportunities. Beyond infectious diseases, mRNA technology is being explored for cancer vaccines, autoimmune diseases, and rare genetic disorders. With strong pipeline momentum and increasing clinical trials globally, the non-COVID-19 segment is expected to accelerate over the next decade. The World Health Organization's 2024 initiative to develop an advanced mRNA vaccine for avian influenza (H5N1) further strengthens future opportunities.

Market Challenges

Public vaccine hesitancy remains a major challenge, particularly in regions with misinformation, low awareness, or weaker healthcare access. Intellectual property conflicts-such as disputes involving Moderna and Arbutus-also impact competitive dynamics. Additionally, the complexity of large-scale mRNA vaccine production, involving sensitive cold storage and advanced lipid nanoparticle delivery systems, poses manufacturing challenges for emerging markets.

Market Trends

Technological Advancements

Key trends include the development of self-amplifying mRNA, improved lipid nanoparticle (LNP) delivery systems, and AI-guided clinical research. These innovations enhance vaccine efficacy, reduce dosing frequency, and lower production costs. Continuous regulatory support from agencies such as the U.S. FDA and EMA is also contributing to faster vaccine innovation cycles.

Strategic Collaborations

Collaborations are rising across the sector. BioNTech's partnership with CEPI in 2023 to develop vaccines for Mpox and malaria reflects strategic global interest in emerging infectious diseases.

Segmentation Insights

By Type:

The COVID-19 vaccines segment dominated in 2024 due to global vaccination campaigns. Meanwhile, the non-COVID-19 vaccine segment is expanding rapidly with RSV, influenza, rabies, and cancer vaccine pipelines growing in clinical significance.

By Indication:

COVID-19 infection held the largest share in 2024 owing to booster requirements and evolving variants. RSV vaccines, including Moderna's FDA-approved mRESVIA (2024), show strong growth potential.

By Distribution Channel:

Hospital and retail pharmacies led the market in 2024 due to large-scale vaccination infrastructure established during the pandemic. Government suppliers also contributed significantly through mass immunization programs.

Regional Outlook

North America dominated with USD 3.13 billion in 2024 due to robust research capabilities, strong regulatory frameworks, and large-scale manufacturing.

Europe ranked second, supported by favorable vaccination policies and high acceptance rates.

Asia Pacific is expected to see the fastest future growth, driven by rising infectious disease prevalence and expanding biotech investments.

Rest of the World continues to benefit from new manufacturing facilities, such as BioNTech's mRNA plant in Rwanda (2023).

Conclusion

The global mRNA vaccines market is on a dynamic growth trajectory from USD 8.91 billion (2024) to USD 20.43 billion (2032). With expanding applications, technological breakthroughs, and rising global investment, mRNA vaccines are positioned to remain a transformative force in modern medicine.

Segmentation By Type

  • COVID-19 Vaccines
  • Non-COVID-19 Vaccines

By Indication

  • COVID-19 Infection
  • Respiratory Syncytial Virus (RSV) Infection
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Type, Indication, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the mRNA Vaccines Market
  • 4.4. Incidence/Prevalence of Key Diseases, 2024
  • 4.5. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)

5. Global mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. COVID-19 Vaccines
    • 5.1.2. Non-COVID-19 Vaccines
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. COVID-19 Infection
    • 5.2.2. Respiratory syncytial virus (RSV) Infection
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. COVID-19 Vaccines
    • 6.1.2. Non-COVID-19 Vaccines
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. COVID-19 Infection
    • 6.2.2. Respiratory syncytial virus (RSV) Infection
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. COVID-19 Vaccines
    • 7.1.2. Non-COVID-19 Vaccines
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. COVID-19 Infection
    • 7.2.2. Respiratory syncytial virus (RSV) Infection
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. COVID-19 Vaccines
    • 8.1.2. Non-COVID-19 Vaccines
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. COVID-19 Infection
    • 8.2.2. Respiratory syncytial virus (RSV) Infection
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. COVID-19 Vaccines
    • 9.1.2. Non-COVID-19 Vaccines
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. COVID-19 Infection
    • 9.2.2. Respiratory syncytial virus (RSV) Infection
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. CureVac SE
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. GSK plc
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Sanofi
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Pfizer Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Gennova Biopharmaceuticals Limited
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Walvax Biotechnology Co., Ltd.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Arcturus Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 3: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 6: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 7: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America mRNA Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 10: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 11: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 15: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 19: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032a

List of Figures

  • Figure 1: Global mRNA Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global mRNA Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global mRNA Vaccines Market Value Share (%), by Indication, 2024 & 2032
  • Figure 4: Global mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global mRNA Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 8: North America mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 9: North America mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 10: North America mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America mRNA Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America mRNA Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 16: Europe mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 17: Europe mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 18: Europe mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 25: Asia Pacific mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 26: Asia Pacific mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Rest of the World mRNA Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Rest of the World mRNA Vaccines Market Value Share (%), by Type, 2024
  • Figure 32: Rest of the World mRNA Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 33: Rest of the World mRNA Vaccines Market Value Share (%), by Indication, 2024
  • Figure 34: Rest of the World mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Rest of the World mRNA Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Global mRNA Vaccines Market Share (%), By Company, 2024